July 28, 2021 01:05 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Biased, absurd and false; disregard it': Bengal govt tells court on NHRC post-poll violence report | Javed Akhtar defamation: Mumbai court gives 'last chance' to Kangana Ranaut, asks her to attend next hearing | Ex-CBI special director Rakesh Asthana appointed Delhi Police Commissioner | US Secretary of State Antony Blinken arrives in India, to hold talks with leaders tomorrow | BJP picks up Basavaraj Bommai as new CM for Karnataka, Yediyurappa congratulates his successor

DCGI approves DRDO's anti-COVID oral drug '2-DG' for emergency use

New Delhi/IBNS: The Drug Controller General of India (DCGI) has approved the emergency use of DRDO's anti-COVID-19 therapeutic oral drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderation to severe COVID-19 patients.

Covaxin taken off clinical trial mode, no consent forms required

New Delhi/IBNS: Pharmaceutical company Bharat Biotech's indigenous Coronavirus vaccine-Covaxin-has been taken off the clinical trial mode, which means beneficiaries will not have to sign consent forms before taking the drug.

Serum Institute, Bharat Biotech get DCGI approval for emergency use of Covid-19 vaccines

New Delhi/IBNS: Two Covid-19 vaccine candidates-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-on Sunday received the approval of the Drugs Controller General of India (DCGI) for emergency use in India.

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

Covid vaccine approval likely soon : DCGI

New Delhi/IBNS: The coronavirus vaccines awaiting approval can be cleared soon, India's drug control authority said Thursday.

Serum Institute gets DCGI nod to resume Covid-19 vaccine

New Delhi/IBNS: The Serum Institute of India (SII) has got the nod of the Drug Controller General of India (DCGI) to resume the phase two and three trials for Covid-19 vaccine, media reports said. 

After Oxford Covid-19 Vaccine trial pause, DCGI sends show-cause notice to Serum Institute

New Delhi/IBNS: After pharmaceutical giant AstraZeneca halted the Phase 3 study testing of the Oxford Vaccine against Covid-19, the Drugs Controller General of India (DCGI) on Wednesday issued a show-cause notice to Serum Institute of India (SII) for not informing the central drug regulator about the pause of trials in other countries.

'Process as per global norms': ICMR defends Aug 15 deadline for COVAXIN

New Delhi/IBNS: The Indian Council of Medical Research (ICMR) has defended the August 15 launch of COVAXIN, after the scientific community of the country termed the short timeline "risky" and "impossible", a media report said.

India's first COVID-19 vaccine gets DCGI's approval for human trials: Report

Hyderabad/IBNS: India's first homegrown Covid-19 vaccine candidate COVAXIN has received approval from Drug Controller General of India (DCGI) to conduct Phase I and II human trials, said a media report.